



Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401

David J. Chung, Nina Shah, Juan Wu, Brent Logan, Lina Bisharat, Natalie Callander, Giulia Cheloni, Kenneth Anderson, Thinle Chodon, Binod Dhakal, Steve Devine, Poorvi Somaiya Dutt, Yvonne Efebera, Nancy Geller, Haider Ghiasuddin, Peiman Hematti, Leona Holmberg, Alan Howard, Bryon Johnson, Dimitra Karagkouni, Hillard M. Lazarus, Ehsan Malek, Philip McCarthy, David McKenna, Adam Mendizabal, Ajay Nooka, Nikhil Munshi, Lynn O'Donnell, Krina Patel, Aaron P. Rapoport, Jane Reese, Jacalyn Rosenblatt, Robert Soiffer, Dina Stroopinsky, Lynne Uhl, Ioannis S. Vlachos, Edmund K. Waller, James W. Young, Marcelo C. Pasquini, and David Avigan

In the original version of this article (1), author Krina Patel is mistakenly omitted from the author list. The error has been corrected in the latest online HTML and PDF versions of the article and the author contributions and disclosures have been updated as necessary. The authors regret the error.

Reference

1. Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, et al. Randomized phase II trial of dendritic cell/myeloma fusion vaccine with lenalidomide maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: BMT CTN 1401. *Clin Cancer Res* 2023;29:4784–96.

Published online October 1, 2024.

Clin Cancer Res 2024;30:4542

doi: 10.1158/1078-0432.CCR-24-2408

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

©2024 The Authors; Published by the American Association for Cancer Research